CBP-201 is an extremely potent monoclonal antibody against IL-4Rα, a receptor found on immune cells that mediates the biological activities of both IL-4 and IL-13, two important cytokines that drive allergic inflammation such as asthma and atopic dermatitis. Extensive preclinical and clinical studies have shown that blocking IL-4Rα reduces inflammation in a wide variety of allergic inflammatory conditions.  CBP-201 was discovered internally and is wholly-own by Connect. IND filing is expected in Q1 2018.

TEL/FAX: 0512-53577866

E-MAIL: qchang@connectpharm.com

ADD: 10th Floor, XiangTang Development Building #3 ChaoYang Dong Road, Taicang,Jiangsu Province, China ,215400

Copyright: Suzhou Connect Biopharmaceuticals, Ltd.

Technical support: Epower